Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for April 2007
April 2, 2007
- FDA Approves Janumet for Type 2 Diabetes, Offering Powerful Glucose Control of a DPP-4 Inhibitor and Metformin in a Single Tablet
- Baxter Announces FDA Approval Of Ceprotin For Severe Congential Protein C Deficiency
- Interpublic to Participate in J&J Media Review
- Novartis Suspends Canadian Marketing and Sales of Zelnorm in Response to Request From Health Canada
- Roche Acquires THP in $56.5 Million Deal
- INEX Extends Timeline for Completing Spin-out of Tekmira Pharmaceuticals Corporation
- Abbott Seeks U.S. and E.U. Regulatory Approval for Humira (Adalimumab) in Psoriasis
- IMPAX Settles Oxycontin Litigation; Amends Marketing Agreement with DAVA Pharmaceuticals
- NeoPharm Provides Update on LE-SN38 Program
- Cephalon Provides Update Related to Nuvigil New Drug Application
- Auriga Laboratories Expects Q1 2007 Gross Revenue to Exceed a Record $8 Million
- EPIX Provides Update Regarding Status of Vasovist Appeal
- Boehringer Ingelheim: Media Statement
- The Transfer of All Commercial Rights for Panaldine
- FDA Approves Rhophylac for the Treatment of Immune Thrombocytopenic Purpura (ITP)
- GlaxoSmithKline K.K. Seeks Approval in Japan for Lapatinib, a New Treatment for Breast Cancer
- FDA Approves Accelerated Dosing Schedule for GlaxoSmithKline's Twinrix
- Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment
- Genencor's Technology for Production of Secreted Polypeptides Licensed by Pfizer
- Pharmaceutical Federal Lobbying Spending Flourishes
- PerkinElmer Acquires Improvision Ltd.
- Sun Pharma Announces Approval of Demerger by High Court and Fixing of Record Date 30 April 2007
- Fitzpatrick Cella Wins Appeal on Behalf of Merck & Co. in Trusopt Patent-Infringement Case
- Pharmacia Subsidiaries Reach $34.7 Million Settlement with DOJ; Resolve Allegations of Improper Activities Prior to Acquisition by Pfizer
- Publicis Groupe to Expand Further in China: Acquires Majority Stake in Yong Yang, Leading Marketing Services Group
- Fitzpatrick Cella Wins Appeal on Behalf of Merck & Co. in Trusopt Patent-Infringement Case
April 3, 2007
- Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa
- Beijing Med-Pharm Corporation and Alliance Boots plc Joint Venture Acquisition Plans Approved by Guangzhou Pharmaceuticals Company Ltd. Shareholders
- AmerisourceBergen to Acquire Xcenda LLC
- Codexis and Merck Sign Technology Collaboration
- New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia
- Nipent Acquisition by Hospira is Complete
- Wyeth Completes Purchase of Wyeth K.K. Japan
- MediVas Announces Achievement of Milestone in Connection With Merck Agreement
- New Data Confirm That Use of Levemir Can Limit Weight Gain
- Fewer Children and Teens Received Antidepressants Following FDA Warnings
- Bristol-Myers Squibb Gets Civil Investigative Demand From FTC
- Boston Scientific Announces Japanese Approval for the Taxus Express2 Stent System
- Lilly Announces Completion of Hypnion Acquisition
- Crucell Announces European Protein Distribution Deal with Talecris Biotherapeutics
- Managing Diabetes is Now Simpler and More Convenient with New Premixed Insulin Analogue
April 4, 2007
- Innocoll Receives FDA Approval to Commence Phase 2 Clinical Development with its CollaRx Bupivacaine Implant for the Management of Post-operative Pain
- Cerimon Pharmaceuticals Initiates ARREST UC-1, a Global Phase 2b Study of Basiliximab in Patients with Steroid-Refractory Ulcerative Colitis
- Applied DNA Sciences Acquires Applied DNA Sciences Europe Ltd.
- Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
- Lux Biosciences Initiates Clinical Trials of Its Second Pivotal Stage Program
- Effect of Hormone Therapy on Risk of Heart Disease May Vary by Age and Years Since Menopause
- Britain's OFT Launches Market Study Into UK Medicines Distribution
- Icagen Terminates Phase III ASSERT Study
- New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
- Study Suggests Some Drug Resistance to Influenza B Medications
- Combination Treatment for Migraine More Effective Than Single Medications
- pSivida Signs $165 Million(US) Collaborative Research and Licensing Agreement with Pfizer
- Genzyme Files for Expanded Label for Campath as First-Line Treatment For B-CLL Patients
- Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Pilot Study of MM-093 in Patients with Autoimmune Uveitis
- Manhattan Pharmaceuticals Announces License Agreement and Expanded Pipeline
- Marshall Edwards, Inc. Renegotiates Annual License Payments for Phenoxodiol
- AVEO Enters into Worldwide License and Development Agreement with Schering- Plough for AV-299, AVEO's Novel Anti-HGF Antibody
- Metabasis Therapeutics Initiates a Proof of Concept Study for MB07803, Its Second Product Candidate for the Treatment of Type 2 Diabetes
- Genta Appeals FDA Decision on Genasense in CLL
- Pharmacyclics' Xcytrin New Drug Application for Treatment of Lung Cancer Brain Metastases to Be Filed Over Protest
- Bayer Healthcare Pharmaceuticals Officially Launches in the United States
- Shionogi Announces Revisions to the Second Medium-Term Business Plan
- Shionogi & Co., Ltd. - Notice of Revision of Results Forecast for the Year Ended March 31, 2007
- Roche to Acquire BioVeris for $21.50 Per Share
- Roche to Acquire Bioveris to Expand Its Leading ECL Immunochemistry Business Into New Market Segments
- Meditrina Pharmaceuticals, Inc. Initiates Phase II Trial and Raises $4.4M in Initial Funding
- DOR BioPharma Announces Initiation of Clinical Development Program for Oral Leuprolide
- Biopure Announces CEO's Prepared Remarks at Annual Meeting of Stockholders
- Crucell Announces Start of Rabies Phase I Antibody Cocktail Clinical Study in India four months after launching initial US Trial
- New Report: Allowing the Government to Negotiate Medicare Drug Prices Would Save Taxpayers $30b Annually
- Medifacts International Divests CRO Division
- Regulatory Approval to Start Pediatric Clinical Trials for Japanese Encephalitis (JE) Vaccine in India Obtained
April 5, 2007
- ADVENTRX Grants Manufacturing Contract for ANX-514 (Docetaxel Emulsion)
- One of the Largest-Ever Parkinson's Disease Studies Initiated Across the United States
- Pegintron Approved in China for Treating Chronic Hepatitis B
- Wyeth Provides Guayama Update
- Low-Dose Steroid Combined With Lenalidomide Prolongs Survival Compared With High-Dose Steroid for Multiple Myeloma Treatment
- Cleveland BioLabs Phase II Hormone-Refractory Prostate Cancer Trial Advances to Next Phase
- Multiple Myeloma Clinical Trial Closes Early Due to Significantly Superior Results of Comparative Treatment
- R&D Directions Magazine Names Rexahn's Leading Cancer Candidate, RX-0201 (Archexin) among ''100 Great Investigational Drugs''
- BioMS Medical's Pivotal Multiple Sclerosis Trial Receives Positive Interim Safety Analysis
April 6, 2007
- ARIAD Provides Update Regarding AP23573 Phase 3 Trial in Metastatic Sarcoma
- VaxGen to Receive $11M, Release From Potential Liabilities Under Settlement Agreement with U.S. Government; Conference Call Scheduled for Today
- MediMedia USA Acquires Majority Interest in Complete Healthcare Communications, Inc. (CHC)
- Treatment-Induced Growth Factor Causes Cancer Progression
- Sen. Grassley Seeks Marketing and Safety Documents from Major Drug Maker
- Statins Linked to Lower Risk of Infection
- Childhood Immunization Against Pneumonia Cuts Hospital Admissions by Almost 40%
- Barr Confirms Patent Challenge of Ambien CR
- FDA approves Cangene's HepaGam B for a Second Indication; for Use in Hepatitis B-positive Liver Transplant Recipients
- Abbott Announces FDA Approval of a New Coated Niaspan Tablet
- Wyeth Provides Update on FDA Review of the Torisel New Drug Application
- FDA MedWatch Announces Tigan (trimethobenzamide hydrochloride) - Product Market Withdrawal Due to Lack of Evidence of Effectiveness
April 9, 2007
- Melior Enters Research Collaboration With Pfizer
- Ithaka Acquisition Corp. Affiliates Announce Purchase Plan
- Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Glufosfamide in Patients With Soft Tissue Sarcoma
- Patent and Trademark Office Issues Notice of Allowance on Barr's Reissue Application for Seasonale '032 Patent
- Caliper Life Sciences to Explore Novel Indications for Drug Candidates
April 10, 2007
- GSK and Adolor Announce Preliminary Results from Phase 3 Safety Study of Alvimopan (Entereg/Entrareg)
- Public Citizen Calls on FDA to Stop Illegal Celebrex Television Advertisement
- Media Advisory: Voluntary Drug Recall - Ortho-McNeil Pharmaceutical, Inc. Issues a Nationwide Recall of Grifulvin V/Griseofulvin Oral Suspension
- Abbott Agrees With World Health Organization (WHO) Director-General to Expand Access to Kaletra/Aluvia (lopinavir/ritonavir)
- Mylan Increases Fiscal 2007 Adjusted Diluted EPS Guidance to $1.60 - $1.63 Excluding Any Contribution from the Recent Launch of Amlodipine Besylate
- Boehringer Ingelheim Expands GeneGo Licenses to Global Agreement
- FermaVir Pharmaceuticals, Inc. Signs Definitive Agreement to Be Acquired by Inhibitex, Inc.
- Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico
- Pfizer and Renovis Extend Research Collaboration to Identify Small Molecule VR1 Antagonists
- Information Policy Institute Finds Restrictions on Provider-Identifiable Healthcare Data Are Anti-Competitive and Will Not Lower Drug Prices
- Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group
- Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
- FDA Announces Important Notice About Combivir and Ziagen
- Galapagos Issues 628,058 New Shares Related to Inpharmatica Acquisition and Warrant Exercise
- U.S. District Court Grants Extension for Consideration of Amlodipine Besylate Exclusivity
April 11, 2007
- Neurochem's Eprodisate (Kiacta) PDUFA Date Extended Three Months by FDA
- Statement by Merck & Co., Inc. Regarding FDA Arthritis Drugs Advisory Committee Meeting on Arcoxia (etoricoxib)
- Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
- Transgene and Roche Enter Partnership on Therapeutic Vaccines Against HPV-Mediated Diseases
- Illumina Announces Consolidation of Connecticut Operations
- inVentiv Health Announces the Consolidation and Strengthening of its Sampling and Regulatory Compliance Offerings
- Pro-Pharmaceuticals Receives Letter from the FDA for New Drug Application for Davanat/ 5-FU
- Genaera Corporation Completes Strategic Review and Announces Plan to Focus Resources on Obesity and Asthma Programs
- District Court Calls for GlaxoSmithKline to Release Bond Amount of $3 Million to Roxane Laboratories Relating to the Launch of Generic Fluticasone Propionate
- Phenomenex, Global Leader in Separation Sciences Technology, Announces Acquisition of Two Companies in Italy and Denmark
- Publicis Groupe Acquires The McGinn Group, Bolstering Manning Selvage & Lee's Strengths inCorporate Communications
- Ranbaxy Receives Approval To Market Cefprozil Tablets and Cefprozil Powder For Oral Suspension in Canada
- Interpublic Acquires Best-in-Class Search Marketing Agency
- Third Point Demands that PDLI CEO Mark McDade be Terminated or Resign; Insists that Company Pursue Cost Cutting Measures and Consider Alternatives to Maximize Shareholder Value
April 12, 2007
- Genentech Announces First Quarter 2007 Results
- Array BioPharma Achieves Milestone for Dosing MEK Inhibitor, ARRY-704, in Phase 1 Clinical Trial
- Indevus and Valera Announce Merger Exchange Ratio
- Coley Pharmaceutical Group Licenses VaxImmune(TM) to Merck for Use in Vaccine Programs
- MedImmune Explores Strategic Alternatives
- Zanaflex (tizanidine hydrochloride) Tablets and Capsules - Changes to the Contraindications and Warnings Sections of the Approved Product Labeling
- U.S. Federal Circuit Court Affirms Judgment for Allergan, Inc. and Roche Palo Alto, LLC against Apotex, Inc., Apotex Corp., and Novex Pharma in Ketorolac Patent Infringement Lawsuit
- GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth Factor, Promacta, in ITP
- A Genetic 'Gang of 4' Drives Spread of Breast Cancer
- Lupin Receives US FDA Approval for Novel Formulation of Suprax Suspension
- Chromos Plans to Restructure
- Virax to Receive Milestone Payment from Transgene through Co-X-Gene Technology Licence
April 13, 2007
- GSK Announces FDA Approval of Altabax (Retapamulin Ointment), 1%
- FDA Advisory Committee Recommends Against Approval for Merck's NDA for Arcoxia (etoricoxib)
- Merck Anticipates Higher Than Expected First-Quarter Results; Raises Full-Year 2007 Earnings Per Share Guidance
- FDA to Hold Public Hearing on Medication Guide Program
- CDC Changes Recommendations for Gonorrhea Treatment Due to Drug Resistance
- pSivida Sells AION Diagnostics Subsidiary
- National Kidney Foundation Releases Preliminary Anemia Guideline Update
- Baraclude (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
- Eisai Withdraws Application for Additional Indication of Aricept for Treatment of Severe Alzheimer's Disease in Europe
- Syndax Pharmaceuticals, Inc. Licenses Selective Histone Deacetylase Inhibitor MS-275
- Avista Capital Partners Completes Acquisition of BioReliance Corporation from Invitrogen Corporation
- Federal Court Dismisses Vioxx Securities Class Action
- FDA Approves New Dose of Risperdal Consta for Schizophrenia Treatment
- Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
- Invitrogen Completes Divestiture of BioReliance
April 16, 2007
- Lilly Reports Strong First-Quarter Results; Raises Full-Year Sales and EPS Guidance
- Cytochroma and Genzyme Settle Lawsuit
- Ariad Files Claim Against Amgen and Wyeth Alleging Infringement of NF-(kappa)B Patent by Enbrel and Kineret
- FDA Accepts GPC Biotech's Satraplatin NDA for Filing and Grants Priority Review Status
- Avant Restructures Organization to Focus Resources on Core Programs and Operations
- Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C
- U.S. Government Notifies Bavarian Nordic of Intent to Acquire 20 Million Doses of Imvamune Smallpox Vaccine
- Boston Scientific Resolves CRM Warning Letter Deficiencies
- Results of Extraordinary General Meeting held on 16 April 2007
- Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
April 17, 2007
- Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration Enters Development
- Reclast Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone
- VioQuest Pharmaceuticals Signs Definitive Agreement for Sale Valued Up to $3 Million of Chiral Quest Subsidiary
- Johnson & Johnson Reports 2007 First-Quarter Results: Sales Increase of 15.7% and EPS of $.88 Versus $1.10 a Year Ago; Excluding Special Items, EPS was $1.16, an increase of 17.2% *
- Cegedim SA's Proposed Acquisition of Dendrite International, Inc. Clears U.S. Antitrust Review
- FDA Approves New Actonel Dose to Treat and Prevent Postmenopausal Osteoporosis
- Merck Submits New Cross-Protection Data for Gardasil to the FDA and Seeks New Indications for Vaginal and Vulvar Cancers
- Eisai Announces Completion of Acquisition of Morphotek
- Catalina Marketing Agrees to be Acquired by Hellman & Friedman for $32.50 Per Share in Cash
- FDA Licenses First U.S. Vaccine for Humans Against Avian Influenza
- Warner Chilcott Announces Settlements in Principle of Antitrust Suits Brought by States and Indirect Purchasers
- Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
- GE Healthcare Acquires Wave Biotech LLC, Broadening Capabilities in Growing Biopharmaceutical Manufacture Segment
- Patheon Announces Plans to Restructure Canadian Site Network
- FDA Approves First U.S. Vaccine for Humans Against the Avian Influenza Virus H5N1
April 18, 2007
- Abbott Reports 15.5 Percent Sales Growth in First Quarter
- MCF Corporation Closes on the MedPanel, Inc. Transaction
- Anemia Treatment for Patients with Kidney Disease Can Differ by Dialysis Facility Type
- Benefits of Antidepressants Appear Greater Than Risks for Children, Teens
- Cortex's AMPAKINE CX717 Toxicology Data Package Submitted to FDA
- Health Industry Insights Identifies Pharmaceutical Industry's Top Roadblocks to RFID Adoption
- Roche Posts Strong First Quarter Sales – Upgrade of Core Earnings Per Share Outlook for 2007
- Breakthrough Cancer Drug Avastin Approved in Japan for Use in Advanced or Recurrent Colorectal Cancer
- Phoenix Marketing International's Health Care Practice Quantifies Consumer Confidence in Pharmaceutical and Medical Websites
- INC Research Expands Therapeutic Focus with Infectious Disease Capabilities
- Cell Therapeutics, Inc. to Pay United States $10.5 Million to Resolve Claims for Illegal Marketing of Cancer Drug
- CTI Settles Qui Tam Suit with Government, Suit Against Medicare Reimbursement Advisor to Recover Damages Filed
- S&P: Fourth Annual "Top 10 Pharma Products To Watch" Report Published
- Large Numbers of People Are Not Very Confident in Their Own Knowledge and the Safety of Prescription Medications and This Often Leads to Non-Adherence
- New Report Shows Prices for Top Medicare Part D Drugs Grew by 9.2 Percent in Past Year
- New Study Reveals Generic Drugs Continue Entering Market as Authorized Generic Competition Increases
- Entelos Acquires SPRM Compound Series
- Med Ad News Honors Health-Care Advertisers at 18th Annual Manny Awards
April 19, 2007
- Baxter Reports Strong First Quarter Financial Results and Boosts Full-Year Outlook
- Wyeth Reports Earnings Results for the 2007 First Quarter
- Wyeth Responds to Special Report Published in New England Journal of Medicine
- Antisoma Announces Global Agreement with Novartis for Cancer Drug AS1404
- Schering-Plough Reports Financial Results for First Quarter of 2007
- Neurochem Update on the North American Phase III Clinical Trial for Tramiprosate (ALZHEMED) for the Treatment of Alzheimer's Disease
- Schering-Plough Announces Initiation of Two Phase III Clinical Trials for Novel Selective Antiplatelet Therapy (TRA-SCH 530348)
- PhRMA Statement on Families USA Reports
- Schering-Plough Announces Zetia Approved in Japan for Treatment of High Cholesterol
- Gilead Sciences Announces First Quarter 2007 Financial Results
- Novartis Expands Late-stage Oncology Pipeline With AS1404, a Novel Agent Shown to Break Down Blood Vessels That Support Tumor Growth
- National Medical Association Seeks to Increase Diversity in Clinical Trials
- Access Pharmaceuticals Signs Definitive Merger Agreement With Somanta Pharmaceuticals
- Ovarian Cancer Deaths Due to HRT In UK Since 1991
- NeoPharm, Inc. Announces Strategic Reassessment and Reorganization
- Merck Reports Strong Financial Results for First-Quarter 2007
- Aranesp "145 Study" Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
- First-of-its-Kind Email Newsletter Recaps the Issues Raised by Pharmaceutical Industry Bloggers
- BTG signs agreement with Novacea and KuDOS for AQ4N
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Breaks Ground on New Facility
April 20, 2007
- Pfizer Delivers Solid First-Quarter 2007 Results, Updates Full-Year Expectations for 2007 and 2008
- FDA Grants Full Approval for DepoCyt for the Treatment of Lymphomatous Meningitis
- Nabi Biopharmaceuticals Announces Agreement to Sell Aloprim
- ZARS Announces First European Marketing Approval and License Agreement With EUSA Pharma for Rapydan
- The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
- AHIP Advances New National Strategy to Improve Health Care Safety and Quality
- Abbott Submits New Drug Application for Combination Niaspan/Simvastatin Tablet
- FDA Announces Audio Broadcasts on Emerging Drug Safety Information
April 23, 2007
- Texas Court Dismisses Claim of Vioxx User Who Said Merck Failed to Properly Warn of the Alleged Risks
- KaloBios Licenses Humaneering Technology to Major Pharmaceutical Company
- CollaGenex Pharmaceuticals Provides Update on Examination of Incyclinide Patent Application
- AstraZeneca Announces Decision to Discontinue Collaboration With AtheroGenics Regarding AGI-1067
- AstraZeneca PLC: First Quarter Results 2007
- AstraZeneca to Acquire MedImmune For $58 Per Share in a Fully Recommended, All-cash Transaction with a Total Enterprise Value of $15.2 Billion
- Novartis with Dynamic Growth in the 2007 First Quarter
- FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer
- Application for an Additional Indication of CombinationTherapy of Glufast® and Insulin Sensitizer in Japan
- Many Americans Deeply Skeptical Of Pharmaceutical Companies-- Motives For Supporting Non-Profits
- Synosia Therapeutics Announces Second Major Pharmaceutical Deal
- Actavis Completes Acquisition of Abrika Pharmaceuticals in the US
- The Westaim Corporation to Undertake Review of Business Strategy
April 24, 2007
- Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 Billion
- Astex Grants Cytochrome P450 License to Glaxosmithkline
- FDA Approves Alpharma's Kadian New 10mg Strength
- FDA Approves First Generic Versions of Ambien (Zolpidem Tartrate) for the Treatment of Insomnia
- Forest Laboratories, Inc. Reports Fiscal Year 2007 Fourth Quarter Revenues of $885,000,000, Reported EPS Loss of ($0.75) and Adjusted EPS of $0.74*, Excluding the Effect of the Cerexa Acquisition
- MultiCell Signs License Agreement With Eisai Japan to Use Fa2N-4 Cell Line for Drug Discovery/ADMETOX Applications
- Drug Reps Use Friendship to Influence Doctors, Says Faculty Member
- China Aoxing Pharmaceutical Company Signs Letter of Intent to Acquire Shijiazhuang Le Ren Tang Pharmaceutical Ltd.
- Drug Company Sales Visits Influenced Doctors, Study Finds
- Acomplia (rimonabant) is Reimbursed in Switzerland for the Treatment of Type 2 Diabetics Overweight Patients and for the Treatment of Patients with Obesity
- SEC Charges Husband of Amgen Vice President with Insider Trading
- Akzo Nobel NV (NL) - Refocused Akzo Nobel reports strong first quarter results
- Elan Reports First Quarter 2007 Financial Results
- Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntington's Disease
- SVB Silicon Valley Bank Provides $19 Million in Buyout Financing for Vector Capital's Acquisition of Tripos
- Dey, L.P. Reaches Settlement with Commonwealth of Massachusetts on Pricing Litigation
- Vernalis plc Announces Intent to Delist from The Nasdaq Stock Market and to Deregister and Terminate its U.S. Reporting Obligations under the Securities Exchange Act of 1934
- Merck's Plan to Win Has Company Poised to Reclaim Position as Industry Leader, Chairman and CEO Tells Stockholders
- Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
April 25, 2007
- QLT Announces that CHMP Will Recommend to the European Commission that Occult Indication be Deleted from the Visudyne Label in European Union
- Shire plc: First Quarter Results - Strong Start to the Year With Upgraded Guidance Now Including New River
- FDA Advisory Committee Recommends Accelerated Approval of Pfizer's Maraviroc for Treatment-Experienced Patients Infected with CCR5-tropic HIV-1
- AmerisourceBergen Receives DEA Order to Temporarily Halt Distribution of Controlled Substances from Its Orlando, Florida Facility
- Biotech Drug Spending Increases 21 Percent Even as Growth in Rx Expenditure Slows
- QLT Announces Q1 Results for 2007
- PhRMA Statement on Medicare Trustees Annual Report
- FDA Sends Alcon Warning Letter Over Ciprodex Literature
- Medtronic Responds to ''Inequitable Conduct'' Decision by U.S. District Court in Stent Litigation
- Novartis Expands Portfolio of Respiratory Medicines
- Dyadic Announces Discovery of Potentially Material Operational and Financial Improprieties at its Hong Kong and Mainland China Operations
- New Indication for Singulair (montelukast sodium) Approved to Prevent Exercise-induced Bronchoconstriction
- GlaxoSmithKline: Results Announcement for the First Quarter 2007
- Q1/2007: Merck KGaA Total Revenues Grow 37% to EUR 2.2 Billion
- Journal of the American Medical Association Publishes MERLIN TIMI-36 Results
- New Data Supports Safety of Anti-anginal Drug but Not Its Effectiveness in Reducing Recurrent Major Cardiac Events in Patients with Acute Coronary Syndromes
- Orion's Partner Discontinues Development of Levosimendan (Simdax) in the US
- Genzyme Reports Significant Revenue and Earnings Growth in First Quarter
- New Trial Expands Evidence for Glucobay in Prevention of Cardiovascular Diseases
- FDA Approves Labeling Update for Orencia (abatacept) to Inhibit Structural Joint Damage in Adults with Moderate to Severe Rheumatoid Arthritis
- Health Canada Approves Lipitor for the Reduction of the Risk of Heart Attack in Patients with Coronary Heart Disease
- Large Numbers of People Do Not Trust the Institutions They Identify as Most Responsible for Drug Safety
- Questions Over Zyprexa Clinical Trial Data Underscore Need for Congress to Act Now on Drug Safety Legislation
- Roche Carolina Inc. to Expand Manufacturing at Florence Facility
- Solvay Pharmaceuticals Files Tedisamil, a New Cardiometabolic Product for the Treatment of Atrial Fibrillation and Atrial Flutter
- Kirin's NESP Long-Acting Erythropoiesis Stimulating Agent Injection Syringe Receives Approval in Japan
- BioLife Solutions Grants Product License to Centocor Research & Development, Inc.
April 26, 2007
- Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
- Pfizer Subsidiary Pleads Guilty to Kickback Violation and Is Sentenced to Pay Criminal Fine of $19.68 Million
- James M. Cornelius Elected Bristol-Myers Squibb CEO
- Roche Update on Tamiflu for Pandemic Influenza Preparedness
- ImClone Systems Reports First Quarter 2007 Financial Results
- Bayer Exceeds Consensus Estimates for the First Quarter of 2007
- Physician Ties to Drug Industry Stronger Than Ever
- New Finance Committee Report Focuses on Drug Company Grants for Medical Education
- Bristol-Myers Squibb Company Reports First Quarter 2007 Financial Results
- Bristol-Myers Squibb Company Reports First Quarter 2007 Financial Results
- Phoenix Marketing International's Health Care Practice Quantifies Visitor Confidence in Pharmaceutical Websites
- Cerus to Explore Strategic Alternatives for Its Immunotherapy Programs
- Acomplia (rimonabant) is Approved in Brazil for the Treatment of Obese Patients, or Overweight Patients with Associated Risk Factors, Such as Type 2 Diabetes or Dyslipidemia
- Pfizer Focused on Delivering the Value Customers Expect and Shareholders Deserve, CEO Kindler Tells Shareholders
- The New ALTANA Starts with Good First Quarter 2007
April 27, 2007
- Abbott's Humira (Adalimumab) Receives Positive Opinion from European Medicines Agency for the Treatment of Crohn's Disease
- Invega Receives Positive Opinion From European Committee for Human Medicinal Products for Treatment of Schizophrenia
- Hollis-Eden Pharmaceuticals Announces Reorganization
- ArQule and Kyowa Hakko Kogyo Sign Exclusive License Agreement in Asia for ARQ 197, c-Met Inhibitor
- FDA Sends Warning Letter to DUSA Pharmaceuticals Over Actinic Keratosis Treatment Ad
- Cipher Pharmaceuticals Receives Approvable Letter from FDA for CIP-ISOTRETINOIN
- Kyowa Hakko Fiscal 2006 Operating Income up 20.2%
- Submission of NDA for Istradefylline(KW-6002), an Investigational Anti-Parkinson's Disease Drug
- Pharmasset Prices Initial Public Offering
- Inex Pharmaceuticals Announces Expected Completion Date for Spin-out of Tekmira Pharmaceuticals Corporation
- EMEA Issues 15 Opinions
- Wyeth Chief Financial Officer and Vice Chairman Kenneth J. Martin to Leave the Company
- Merck Receives Non Approvable Letter from FDA for Arcoxia (etoricoxib)
- Schering-Plough Announces EU Approval Of Two New Formulations Of Aerius (Desloratadine)
- Werner Wenning at the Annual Stockholders’ Meeting in Cologne: Bayer Off to an Excellent Start in 2007
- Blogs Scrutinize Relationships Between Physicians and Pharmaceutical Sales Reps, Drug Companies and Non-Profits
- Merck Receives Non Approvable Letter from FDA for Arcoxia (etoricoxib)
- Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
- FDA Approves Invega for Long-Term Maintenance Treatment of Schizophrenia
- Abbott Reviews 2006 Accomplishments at Annual Shareholders' Meeting
- Ark Therapeutics Group Announces EMEA Decision on Cerepro Phase II Filing
April 29, 2007
- FDA Approves Once-Daily Veramyst (fluticasone furoate) Nasal Spray for Treatment of Seasonal and Year-Round Allergy Symptoms in Adults and Children as Young as Two Years
- Inspire Announces FDA Approval Of AzaSite
April 30, 2007
- InSite Vision Announces FDA Approval for AzaSite Approval Triggers $19 Million Milestone Payment
- Sangamo BioSciences Announces Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
- FDA Approves Product to Treat Common Bleeding Disorder
- Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
- Sebivo (Telbivudine) Approved in European Union as a New Treatment for Chronic Hepatitis B Patients
- GlaxoSmithKline and Wellcome Trust Announce Partnership to Target Drug-Resistant Hospital Infections
- FDA Approves Lantus SoloStar - A New Prefilled Disposable Insulin Pen For Use With Lantus In People With Type 1 And Type 2 Diabetes
- Duramed's Enjuvia (Synthetic Conjugated Estrogens, B) Tablets Receives Two New FDA Approvals
- Court Grants Hemosol Further Stay Extension
- Sebivo Approved in European Union as a New First-line Treatment for Chronic Hepatitis B
- Cardiome Announces In-Licensing Agreement With Eli Lilly and Company
- Humate-P Approved to Prevent Excessive Bleeding in Patients with von Willebrand Disease Undergoing Surgery
- Mylan Remains the Only Approved ANDA for All Strengths of Amlodipine Besylate Tablets
